Clinical Trial · NCT02488070

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

Overview

This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys\[Ahx\]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.

Sponsor

Stanford University

Phase

Phase 1/2

Contacts

Andrei Iagaru (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02488070

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Linker: Ahx

Eligibility

Inclusion

Known diagnosis of prostate cancer
Able to remain still for duration of each imaging procedure (about one hour)
Patient has suspected recurrence based on biochemical data (prostate specific antigen \[PSA\] \> 2 ng/mL)

Exclusion

Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
Inability to lie still for the entire imaging time